Total Payments
$321,201
2024 Payments
$75,347
Companies
50
Transactions
700
Medicare Patients
2,302
Medicare Billing
$454,766
Payment Breakdown by Category
Other$298,825 (93.0%)
Food & Beverage$14,454 (4.5%)
Travel$4,649 (1.4%)
Consulting$3,250 (1.0%)
Education$23.85 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $298,825 | 97 | 93.0% |
| Food and Beverage | $14,454 | 526 | 4.5% |
| Travel and Lodging | $4,649 | 73 | 1.4% |
| Consulting Fee | $3,250 | 1 | 1.0% |
| Education | $23.85 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $314,414 | 432 | $0 (2024) |
| ViiV Healthcare Company | $1,600 | 1 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $935.85 | 56 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $636.58 | 40 | $0 (2024) |
| United Therapeutics Corporation | $580.75 | 21 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $267.91 | 12 | $0 (2024) |
| Jazz Pharmaceuticals Inc. | $242.08 | 13 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $221.21 | 10 | $0 (2024) |
| Genentech USA, Inc. | $206.86 | 12 | $0 (2023) |
| GENZYME CORPORATION | $205.33 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $75,347 | 120 | GlaxoSmithKline, LLC. ($74,590) |
| 2023 | $88,083 | 126 | GlaxoSmithKline, LLC. ($87,310) |
| 2022 | $47,395 | 101 | GlaxoSmithKline, LLC. ($46,552) |
| 2021 | $52,454 | 125 | GlaxoSmithKline, LLC. ($51,381) |
| 2020 | $38,054 | 83 | GlaxoSmithKline, LLC. ($37,472) |
| 2019 | $19,018 | 81 | GlaxoSmithKline, LLC. ($16,803) |
| 2018 | $500.37 | 37 | GlaxoSmithKline, LLC. ($187.00) |
| 2017 | $350.07 | 27 | GlaxoSmithKline, LLC. ($117.19) |
All Payment Transactions
700 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| 12/20/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: RESPIRATORY | ||||||
| 12/17/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $13.11 | General |
| Category: Respiratory | ||||||
| 12/16/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 12/10/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $97.20 | General |
| Category: RESPIRATORY | ||||||
| 12/05/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | Cash or cash equivalent | $46.23 | General |
| 12/05/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | Cash or cash equivalent | $40.32 | General |
| 12/02/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 12/02/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 11/21/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | In-kind items and services | $31.92 | General |
| Category: Cardiology | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Travel and Lodging | Cash or cash equivalent | $93.80 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Travel and Lodging | Cash or cash equivalent | $58.26 | General |
| Category: RESPIRATORY | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Travel and Lodging | Cash or cash equivalent | $52.26 | General |
| Category: RESPIRATORY | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $19.36 | General |
| Category: RESPIRATORY | ||||||
| 11/16/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $81.40 | General |
| 11/16/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 11/16/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $23.56 | General |
| 11/15/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $210.90 | General |
| 11/15/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $81.40 | General |
| 11/15/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $39.75 | General |
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $19.90 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: IMMUNOLOGY | ||||||
| 11/08/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Travel and Lodging | Cash or cash equivalent | $171.52 | General |
| Category: RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 299 | 517 | $558,234 | $64,669 |
| 2022 | 13 | 528 | 948 | $423,853 | $111,033 |
| 2021 | 15 | 691 | 1,170 | $507,502 | $134,289 |
| 2020 | 17 | 784 | 1,334 | $531,742 | $144,775 |
Total Patients
2,302
Total Services
3,969
Medicare Billing
$454,766
Procedure Codes
52
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 116 | 268 | $441,389 | $44,746 | 10.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 67 | 96 | $40,224 | $7,046 | 17.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 32 | 47 | $7,802 | $3,528 | 45.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 24 | 36 | $21,888 | $3,325 | 15.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 24 | 25 | $24,271 | $2,527 | 10.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 20 | 20 | $12,060 | $1,963 | 16.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 25 | $10,600 | $1,535 | 14.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 153 | 447 | $307,010 | $77,114 | 25.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 85 | 132 | $41,712 | $11,992 | 28.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 55 | 121 | $30,613 | $9,678 | 31.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 33 | 33 | $11,121 | $3,510 | 31.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 23 | 23 | $9,476 | $2,776 | 29.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 34 | 44 | $9,812 | $2,268 | 23.1% |
| 31500 | Emergent insertion of breathing tube into windpipe using an endoscope | Facility | 2022 | 12 | 12 | $3,408 | $1,376 | 40.4% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2022 | 12 | 15 | $4,545 | $1,297 | 28.5% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2022 | 34 | 34 | $1,258 | $268.73 | 21.4% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Facility | 2022 | 27 | 27 | $1,620 | $246.55 | 15.2% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2022 | 35 | 35 | $2,100 | $240.15 | 11.4% |
| 94375 | Test to measure rate of airflow | Facility | 2022 | 14 | 14 | $518.00 | $160.64 | 31.0% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2022 | 11 | 11 | $660.00 | $105.63 | 16.0% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 179 | 503 | $341,768 | $87,430 | 25.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 73 | 171 | $43,263 | $13,765 | 31.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 92 | 131 | $41,249 | $12,339 | 29.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 60 | 61 | $20,557 | $6,551 | 31.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 31 | 31 | $12,834 | $3,756 | 29.3% |
About Dr. Mohammad Khan, D.O
Dr. Mohammad Khan, D.O is a Pulmonary Disease healthcare provider based in Akron, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/26/2009. The National Provider Identifier (NPI) number assigned to this provider is 1760610919.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mohammad Khan, D.O has received a total of $321,201 in payments from pharmaceutical and medical device companies, with $75,347 received in 2024. These payments were reported across 700 transactions from 50 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($298,825).
As a Medicare-enrolled provider, Khan has provided services to 2,302 Medicare beneficiaries, totaling 3,969 services with total Medicare billing of $454,766. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Akron, OH
- Active Since 06/26/2009
- Last Updated 05/04/2021
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1760610919
Products in Payments
- AREXVY (Drug) $102,169
- TRELEGY ELLIPTA (Drug) $99,067
- NUCALA (Biological) $41,256
- ANORO ELLIPTA (Drug) $8,697
- ANORO (Drug) $7,460
- DUPIXENT (Biological) $426.54
- SPIRIVA RESPIMAT (Drug) $291.13
- SYMBICORT (Drug) $253.84
- OFEV (Drug) $252.49
- FASENRA (Biological) $224.57
- TYVASO (Drug) $216.90
- BREZTRI (Drug) $202.03
- Xolair (Biological) $168.86
- Yupelri (Drug) $151.85
- UPTRAVI (Drug) $148.75
- XYWAV (Drug) $127.79
- AIRSUPRA (Drug) $127.77
- OPSUMIT (Drug) $119.16
- GLASSIA (Biological) $107.89
- Haegarda (Biological) $107.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Akron
Dr. Joseph Khabbaza, M.d, M.D
Pulmonary Disease — Payments: $445,738
Pulmonary Disease $445,738
Dr. Amit Diwakar, Md, MD
Pulmonary Disease — Payments: $23,860
Pulmonary Disease $23,860
Kenneth Kretchmer, Md, MD
Pulmonary Disease — Payments: $20,443
Pulmonary Disease $20,443
Shanti Akers, M.d, M.D
Pulmonary Disease — Payments: $8,247
Pulmonary Disease $8,247
Matthew Krauza, Md, MD
Pulmonary Disease — Payments: $7,317
Pulmonary Disease $7,317
Harish Kakarala, Md, MD
Pulmonary Disease — Payments: $5,323
Pulmonary Disease $5,323